Literature DB >> 11601747

Chlamydia pneumoniae infection and acute exacerbation of chronic obstructive pulmonary disease (COPD).

D Karnak1, S Beng-sun, S Beder, O Kayacan.   

Abstract

The objective of the study was to investigate the possible association of Chlamydia pneumoniae (Cpn) in acute exacerbations of chronic obstructive pulmonary disease (COPD) patients. Thirty-eight acutely exacerbated COPD patients and 17 healthy smokers were enrolled in the study, as the study and control groups respectively. Nasopharyngeal swabs and paired serum samples for antibody testing of Cpn (microimmunofluorescence--MIF) were obtained from all subjects. Sputum cultures of COPD patients were also performed. No pathogenic bacteria were isolated from nasopharyngeal swabs in any subject. Serologic evidence of recent Cpn infection was observed in 13 (34%) COPD patients and in one (5%) control subject. The prevalence of Cpn IgG and IgM antibodies representing acute infection were significantly higher in COPD patients than in control subjects (P < 0.05 and P < 0.01 respectively). Prevalence of IgA antibodies and IgG pre-existing antibodies did not show any difference (P > 0.05). Microbiologic culture of the sputa yielded potentially pathogenic micro-organisms in 23 of 38 (60%) COPD patients. Alpha-haemolytic streptococcus (35%), Niesseria spp. (31%) and Candida spp. (9.5%) were most prominent micro-organisms in positive cultures. Although a high prevalence of IgG antibodies against Cpn was detected, it was the sole causative agent in only four (10%) patients. We conclude that a remarkable number of COPD patients (34%) are acutely infected with Cpn and it may either be the sole causative agent or frequently a co-agent in acute exacerbations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601747     DOI: 10.1053/rmed.2001.1159

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  10 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Evolution to a chronic disease niche correlates with increased sensitivity to tryptophan availability for the obligate intracellular bacterium Chlamydia pneumoniae.

Authors:  Wilhelmina M Huston; Christopher J Barker; Anu Chacko; Peter Timms
Journal:  J Bacteriol       Date:  2014-03-28       Impact factor: 3.490

Review 3.  Pathogen-directed therapy in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez
Journal:  Proc Am Thorac Soc       Date:  2007-12

Review 4.  Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease.

Authors:  A J White; S Gompertz; R A Stockley
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

Review 5.  [Triggering factors of acute COPD exacerbations].

Authors:  S Jouneau
Journal:  Rev Mal Respir       Date:  2017-05-02       Impact factor: 0.622

Review 6.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

7.  Role of bacteria in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  Levent Erkan; Oguz Uzun; Serhat Findik; Didem Katar; Ahmet Sanic; Atilla G Atici
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

8.  Gene expression profiles of Chlamydophila pneumoniae during the developmental cycle and iron depletion-mediated persistence.

Authors:  André P Mäurer; Adrian Mehlitz; Hans J Mollenkopf; Thomas F Meyer
Journal:  PLoS Pathog       Date:  2007-06       Impact factor: 6.823

Review 9.  Acute bronchitis: state of the art diagnosis and therapy.

Authors:  Fernando J Martinez
Journal:  Compr Ther       Date:  2004

Review 10.  Chronic bronchial infection in COPD. Is there an infective phenotype?

Authors:  Zinka Matkovic; Marc Miravitlles
Journal:  Respir Med       Date:  2012-12-04       Impact factor: 3.415

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.